Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates

[1] Strosberg J(2017)Phase 3 Trial of N Engl J Med 376 125-135

[2] El-Haddad G(2017)Lu-dotatate for midgut neuroendocrine tumors Neuroendocrinology 105 295-309

[3] Wolin E(2013)ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: peptide receptor radionuclide therapy with radiolabelled somatostatin analogues Eur J Nucl Med Mol Imaging 40 800-816

[4] Hendifar A(2021)The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours Acta Oncol 146 56-73

[5] Yao J(2021)Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms Eur J Cancer 23 2754-2762

[6] Chasen B(2005)Consensus on molecular imaging and theranostics in neuroendocrine neoplasms J Clin Oncol 46 1310-1316

[7] Hicks RJ(2005)Radiolabeled somatostatin analog [ J Nucl Med 6 501-510

[8] Kwekkeboom DJ(2016)Lu-DOTA Theranostics 10 35-103S

[9] Krenning E(2020), Tyr EJNMMI Res 58 97S-213

[10] Bodei L(2017)]octreotate in patients with endocrine gastroenteropancreatic tumors J Nucl Med 41 211-1489

[1] Strosberg J(2017)Phase 3 Trial of N Engl J Med 376 125-135

[2] El-Haddad G(2017)Lu-dotatate for midgut neuroendocrine tumors Neuroendocrinology 105 295-309

[3] Wolin E(2013)ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: peptide receptor radionuclide therapy with radiolabelled somatostatin analogues Eur J Nucl Med Mol Imaging 40 800-816

[4] Hendifar A(2021)The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours Acta Oncol 146 56-73

[5] Yao J(2021)Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms Eur J Cancer 23 2754-2762

[6] Chasen B(2005)Consensus on molecular imaging and theranostics in neuroendocrine neoplasms J Clin Oncol 46 1310-1316

[7] Hicks RJ(2005)Radiolabeled somatostatin analog [ J Nucl Med 6 501-510

[8] Kwekkeboom DJ(2016)Lu-DOTA Theranostics 10 35-103S

[9] Krenning E(2020), Tyr EJNMMI Res 58 97S-213

[10] Bodei L(2017)]octreotate in patients with endocrine gastroenteropancreatic tumors J Nucl Med 41 211-1489